Class Action Champion

An ongoing investigation is examining claims that Novo Nordisk did not adequately warn patients that semaglutide drugs—Ozempic, Wegovy, and Rybelsus—could be linked to non-arteritic ischemic optic neuropathy (NAION) and sudden, potentially permanent vision loss. People who experienced blurred, dimmed, or sudden one-eye vision loss while taking or soon after stopping these medications may be affected. Consumers can protect their rights by documenting symptoms and diagnosis and submitting the confidential intake form to be evaluated for participation in the GLP-1 MDL.

Attorneys are investigating whether companies that use AI to screen or interview job applicants—and the vendors supplying those tools—may be violating the Fair Credit Reporting Act by generating “consumer report”-like assessments without required disclosures, consent, accuracy safeguards, or dispute procedures. People who applied for jobs in the last two years where AI played a role in screening or interviewing may be affected. To protect your rights and potentially join a future class action, you can submit your experience through the online form to speak with attorneys at no cost.

Attorneys working with ClassAction.org are investigating whether Google unlawfully monopolized the digital display advertising services market, allegedly blocking rivals and inflating prices through its ad tech tools and auction practices. The investigation may affect advertisers who bought Google Display Ads and paid more than they would have in a competitive market. Eligible advertisers can protect their rights by signing up through a secure form to join a coordinated mass arbitration process at no upfront cost.